Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: A multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the mayo phase II consortium and the cancer therapeutics research group

Journal of Clinical Oncology

Volumn 30, Issue 27, 2012, Pages 3361-3367

  Yeo, Winnie ^a   Chung, Hyun C ^b   Chan, Stephen L ^a   Wang, Ling Z ^c   Lim, Robert ^c   Picus, Joel ^d   Boyer, Michael ^e   Mo, Frankie K F ^a   Koh, Jane ^a   Rha, Sun Y ^b   Hui, Edwin P ^a   Jeung, Hei C ^b   Roh, Jae K ^b   Yu, Simon C H ^a   To, Ka F ^a   Tao, Qian ^a   Ma, Brigette B ^a   Chan, Anthony W H ^a   Tong, Joanna H M ^a   Erlichman, Charles ^f   Chan, Anthony T C ^a   Goh, Boon C ^c   more..

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Yonsei University College of Medicine   (South Korea)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SYDNEY CANCER CENTRE   (Australia)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BELINOSTAT; BIOLOGICAL MARKER; PROTEIN HR23B; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DYSPNEA; EPIGENETICS; EXPLORATORY RESEARCH; FATIGUE; FEMALE; FEVER; HICCUP; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; INJECTION SITE REACTION; INSOMNIA; LIVER CELL CARCINOMA; LIVER HISTOLOGY; LIVER RUPTURE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ORAL MUCOSITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PEPTIC ULCER BLEEDING; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QT PROLONGATION; RASH; SCORING SYSTEM; SIDE EFFECT; SUDDEN DEATH; TASTE DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; URINARY FREQUENCY;

EID: 84866758581     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.2395     Document Type: Article

References (34)

1. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
2. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009
3. Esteller M: Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 94:179-183, 2006
4. Yang B, Guo M, Herman JG, et al: Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 163:1101-1107, 2003 (Pubitemid 37040145)
5. Zhong S, Yeo W, Tang MW, et al: Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin Cancer Res 9:3376-3382, 2003 (Pubitemid 37086674)
6. Zhong S, Tang MW, Yeo W, et al: Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res 8:1087-1092, 2002 (Pubitemid 35177360)
7. Coradini D, Speranza A: Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Acta Pharmacol Sin 26:1025-1033, 2005 (Pubitemid 41296939)
8. Chiba T, Yokosuka O, Arai M, et al: Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol 41:436-445, 2004 (Pubitemid 39158753)
9. Herold C, Ganslmayer M, Ocker M, et al: The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36:233-240, 2002 (Pubitemid 34146430)
10. Yamashita Y, Shimada M, Harimoto N, et al: Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 103:572-576, 2003 (Pubitemid 36091459)
11. Svechnikova I, Gray SG, Kundrotiene J, et al: Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol 22:579-588, 2003
12. Armeanu S, Pathil A, Venturelli S, et al: Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 42:210-217, 2005 (Pubitemid 40143467)
13. Plumb JA, Finn PW, Williams RJ, et al: Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2:721-728, 2003
14. Qian DZ, Kato Y, Shabbeer S, et al: Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589. Clin Cancer Res 12:634-642, 2006 (Pubitemid 43166159)
15. Pathil A, Armeanu S, Venturelli S, et al: HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 43:425-434, 2006
16. Ma BB, Sung F, Tao Q, et al: The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs 28:107-114, 2010
17. Venturelli S, Armeanu S, Pathil A, et al: Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 109:2132-2141, 2007 (Pubitemid 46744210)
18. Khan O, Fotheringham S, Wood V, et al: HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A 107:6532-6537, 2010
19. Le Tourneau C, Lee JJ, Siu LL: Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708-720, 2009
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Wang LZ, Chan D, Yeo W, et al: A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci 878:2409-2414, 2010
22. Metz CE: Basic principles of ROC analysis. Semin Nucl Med 8:283-298, 1978
23. Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 39:561-577, 1993 (Pubitemid 23118304)
24. Wang L, Goh BC, Lwin TW, et al: Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma. J Clin Oncol 28:225s, 2010 (suppl; abstr 2585)
25. Steele NL, Plumb JA, Vidal L, et al: A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14: 804-810, 2008 (Pubitemid 351231163)
26. Gimsing P, Hansen M, Knudsen LM, et al: A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 81:170-176, 2008
27. Shah MH, Binkley P, Chan K, et al: Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12:3997-4003, 2006 (Pubitemid 44078086)
28. Molife R, Fong P, Scurr M, et al: HDAC inhibitors and cardiac safety. Clin Cancer Res 13: 1068, 2007; author reply 1068-1069
29. Piekarz RL, Bates SE: Epigenetic modifiers: Basic understanding and clinical development. Clin Cancer Res 15:3918-3926, 2009
30. Prince HM, Bishton MJ, Harrison SJ: Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958-3969, 2009
31. Steele N, Finn P, Brown R, et al: Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 100:758-763, 2009
32. Fotheringham S, Epping MT, Stimson L, et al: Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15:57-66, 2009
33. Badros A, Burger AM, Philip S, et al: Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 15:5250-5257, 2009
34. Emanuele S, Lauricella M, Carlisi D, et al: SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 12:1327-1338, 2007 (Pubitemid 46890392)